(Q36351998)

13 August 2017

1 reference

title

Conivaptan: a selective vasopressin antagonist for the treatment of heart failure (English)

1 reference

13 August 2017

0 references

1

Ernst R Schwarz

1 reference

13 August 2017

Pramod Sanghi

2

1 reference

13 August 2017

1 January 2006

1 reference

Expert Review of Cardiovascular Therapy

13 August 2017

1 reference

13 August 2017

4

1 reference

13 August 2017

1

1 reference

13 August 2017

17-23

1 reference

Lifetime Risk for Developing Congestive Heart Failure

13 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Is the prognosis of heart failure improving?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Hormones and hemodynamics in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Vasopressin: a new target for the treatment of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

The osmoregulation of vasopressin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Regulation of protein synthesis in ventricular myocytes by vasopressin. The role of sarcoplasmic/endoplasmic reticulum Ca2+ stores

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

The role of arginine vasopressin and its receptors in the normal and failing rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Cell cycle-dependent coupling of the vasopressin V1a receptor to different G proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Renal aquaporin water channels: from molecules to human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Upregulation of aquaporin-2 water channel expression in chronic heart failure rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Hemodynamic effects of infused arginine vasopressin in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Hormonal, global, and regional haemodynamic responses to a vascular antagonist of vasopressin in patients with congestive heart failure with and without hyponatraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.1.17

21 January 2018

Identifiers

DOI

10.1586/14779072.4.1.17

1 reference

13 August 2017

1 reference

PubMed ID

16375624